A sharp spike in generic drug prices that triggered an investigation in Connecticut continues to deepen. The antitrust case that alleges price-fixing and widespread collusion between generic drug companies to divvy up markets and avoid competition has now grown to include attorneys general in 49 states seeking action against 18 companies and two executives for activity involving an expanding list of widely-used drugs. We spoke to Joseph Nielsen, assistant attorney general in the Antitrust Department of the Connecticut Office of the Attorney General, about the case, how it has evolved, and its implications for generic drugmakers, consumers, and the healthcare system.
